CHSY2 Blocking Peptide
- Known as:
- CHSY2 Blocking Peptide
- Catalog number:
- 33r-7264
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- CHSY2 Blocking Peptide
Related genes to: CHSY2 Blocking Peptide
- Gene:
- CHPF NIH gene
- Name:
- chondroitin polymerizing factor
- Previous symbol:
- -
- Synonyms:
- CSS2, CHSY2
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 2008-01-29
- Date modifiied:
- 2015-09-11
Related products to: CHSY2 Blocking Peptide
Related articles to: CHSY2 Blocking Peptide
- Biologic therapies have transformed the management of severe asthma, yet many patients in routine care remain symptomatic. Most real-world data originate from tertiary centers and may not reflect broader healthcare delivery. - Source: PubMed
Publication date: 2026/08/14
Portel LNocent-Ejnaini CParrat EVerdoire PMaurer CF Goupil FTexier NHervy SRaherison-Semjen CMorel HHumbert M - This study evaluated the association of Chuanhuang Patent Formula (CHPF) with short-term renal function parameters and long-term prognosis in patients with acute kidney injury (AKI) on chronic kidney disease (CKD) (A on C) and explored potential subgroups that might derive greater benefit. This retrospective cohort included 205 patients with A on C admitted between January 2016 and October 2025. After 1:1 propensity score matching, 81 patients were included in each group. The primary composite outcome was progression to CKD stage 5, maintenance renal replacement therapy initiation, or all-cause mortality, while secondary outcomes evaluated renal function parameters at 2 and 4 weeks. Renal function parameters were more favorable in the CHPF group at 2 and 4 weeks after treatment initiation. Long-term survival analysis showed that CHPF treatment was associated with a lower risk of the primary outcome (hazard ratio [HR] = 0.56; 95% confidence interval [CI]: 0.32-0.98; = 0.041). Notably, hypertension-stratified subgroup analysis showed that the association between CHPF treatment and outcome-free survival appeared more evident in patients with comorbid hypertension ( = 0.045), whereas no significant difference was observed in patients without hypertension ( = 0.26). In conclusion, CHPF could be a promising adjunctive therapeutic strategy for patients with A on C and was associated with more favorable 2- and 4-week renal function parameters and long-term outcome-free survival. Patients with comorbid hypertension might represent a potential subgroup that could derive greater benefit from CHPF treatment; however, this exploratory finding should be interpreted cautiously and validated in prospective studies. - Source: PubMed
Publication date: 2026/08/13
Zhang YifanWang ZhongWang QiuhanSong ZhiyongGong Xuezhong - Sea cucumber is a high-value marine food that contains characteristic bioactive components, notably saponins and polysaccharides. Strategies promoting their biosynthesis to improve sea cucumber quality are vital for the industry. The impacts of three dietary yeast β-glucans (native β-glucan, ultrasonic-degraded low-molecular-weight β-glucan, and carboxymethylated β-glucan) on the biosynthesis of saponin and fucosylated chondroitin sulfate (FCS) in A. japonicus and the underlying mechanism were investigated. A 28-day feeding trial showed that modified β-glucans improved growth performance and immune responses, as well as elevated the body wall accumulation of saponin and FCS. Mechanistically, modified β-glucans up-regulated the genes involved in the saponin and FCS biosynthesis, including the core mevalonate pathway (hmgcr, mvk, mvd), downstream post-squalene modifications (sqle), and chondroitin backbone biosynthesis (xylt1, chsy1, chpf). Moreover, these β-glucans up-regulated the TLR-MAPK signaling axis genes (tlr, myd88, irak4, traf6, tak1, mkk1, erk, p38) and increased p38/ERK protein abundance and phosphorylation levels. In vivo MAPK inhibition attenuated β-glucan-induced saponin and FCS accumulation and the expression of hmgcr, sqle, xylt1, and chsy1. Our findings reveal that modified β-glucans enhance A. japonicus quality by promoting saponin and FCS biosynthesis in association with the TLR-MAPK signaling axis-mediated immune-metabolic crosstalk. - Source: PubMed
Publication date: 2026/08/06
Qi ZezhengZhang ZeyuDai WenyueMa HongmeiGe JunpengYu YutongCheng MenglingZhao WenjianPan ShihuiGu MinBai Nan - An accumulation of evidence underscores the critical importance of both hypoxia and the immune microenvironment in driving the progression of osteosarcoma. Despite advancements in therapeutic strategies, osteosarcoma continues to pose a formidable challenge due to its aggressive nature and high metastatic potential. Nonetheless, the identification of reliable gene signatures that combine information on hypoxia and immune status to predict osteosarcoma prognosis remains an unmet need. - Source: PubMed
Publication date: 2026/06/20
Xie ShangfangYu WenyaoLin RunyeXin Songjian - Immune checkpoint blockade (ICB) therapy offers remarkable clinical advantages for various cancers, but many patients still fail to receive sustained benefits from this treatment. Tumor microenvironment (TME), a multifaceted ecosystem composed of tumor cells, stromal cells, immune cells, and extracellular matrix (ECM), is critical in determining clinical outcomes and ICB response. The major aim of the study was to classify the breast cancer (BRCA) TME into distinct subtypes to predict ICB response, and to uncover the molecular mechanisms involved. - Source: PubMed
Publication date: 2026/05/27
He ZimengXu YunshengWu Chunyan